New obesity drug from Lilly delivers major weight loss

Eli Lilly's investigational obesity drug retatrutide met primary and key secondary endpoints in a phase 3 clinical trial, helping patients lose up to 30 percent of their body weight with a once-weekly injection. The highest dose achieved 28.3 percent weight loss, demonstrating clinically meaningful results.